Cost-effectiveness of ramucirumab plus paclitaxel as maintenance therapy for patients with advanced HER2-negative gastric or gastroesophageal junction cancer
At current pricing and under the existing PAP framework, ramucirumab plus paclitaxel is not a cost-effective switch maintenance strategy in advanced HER2-negative gastric or gastroesophageal junction cancer in China. Significant price reductions through national negotiations may enable this regimen to become economically viable within the Chinese healthcare system.
Authors
- Dong Li (ORCID: https://orcid.org/0000-0002-0642-0589)
- Xue Zhao (ORCID: https://orcid.org/0000-0001-8985-1861)
- Liman Huo (ORCID: https://orcid.org/0000-0003-0078-4047)
- Huixian Jia (ORCID: https://orcid.org/0000-0001-8520-5467)
- Rong Cui
- Afang Cao
Institutions
- Hebei Medical University (CN)
- Second Hospital of Hebei Medical University (CN)
- Fourth Hospital of Hebei Medical University (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2026-02-09
- DOI
- https://doi.org/10.3389/fonc.2026.1713870
- Primary Topic
- Gastric Cancer Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00